NM
MREO

Newtyn Management’s Mereo BioPharma MREO Stock Holding History

Newtyn Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
7,079,056
+6,854,434
+3,052% +$2.94M 0.25% 28
2025
Q4 		$93.6K Buy
+224,622
New +$428K 0.01% 32

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Newtyn Management's MREO Position: Q1 2026 in Review

Newtyn Management increased its Mereo BioPharma (MREO) stake by 3,052% in Q1 2026, buying an estimated $2.94M and bringing the position to 7,079,056 shares worth $2.34M. The position accounts for 0.25% of the portfolio, ranked #28.

Newtyn Management first reported a position in MREO in Q4 2025 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Newtyn Management held 7,079,056 shares of Mereo BioPharma worth $2.34M as of Q1 2026.
  • Newtyn Management bought 6,854,434 Mereo BioPharma shares in Q1 2026, an estimated $2.94M.
  • Mereo BioPharma made up 0.25% of Newtyn Management's portfolio in Q1 2026, its #28 holding.
  • Newtyn Management first reported a position in Mereo BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Newtyn Management's 13F filing for Q1 2026, filed 15 May 2026.